Stockreport

Galecto Reports Third Quarter 2024 Financial Results

Galecto, Inc.  (GLTO) 
PDF -  Completed strategic review to focus on oncology and severe liver diseases -  Announced acquisition of global rights to BRM-1420, a dual ENL-YEATS and FLT3 inhibito [Read more]